Biotech News

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Capricor Therapeutics (CAPR)Capricor Therapeutics2026-06-25 13:46 ESTFDA / regulatory

CAPR (CAPR) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is capr.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics to Present at Upcoming Investor Conferences

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics Expands Commercial Leadership Team

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12

CAPRCapricor Therapeutics2026-06-25 13:46 EST

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

Capricor Therapeutics

Capricor Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States